ロード中...
Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis
Recently, sirolimus, an inhibitor of mammalian target of rapamycin, was reported to decrease chylous effusion in patients with lymphangioleimyomatosis (LAM). We herein report a case of a 34-year-old woman with LAM who developed refractory chylothorax and chylous ascites during sirolimus therapy. In...
保存先:
| 出版年: | Intern Med |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
The Japanese Society of Internal Medicine
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5790722/ https://ncbi.nlm.nih.gov/pubmed/29021448 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.8645-16 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|